Key result
Injectable lipid-lowering therapies cut LDL-C ~50% across CKD stages G3-G5 without dose adjustments.
Why the study?
Do injectable lipid-lowering therapies reduce LDL-C and major adverse cardiovascular events in adults with CKD stages G3-G5, dialysis, or transplant recipients?
Systematic Review (n=28,013)
Do injectable lipid-lowering therapies reduce LDL-C and major adverse cardiovascular events in adults with CKD stages G3-G5, dialysis, or transplant recipients?
Answers are grounded in this paper and cite their sources.
Injectable lipid-lowering therapies provide substantial LDL-C reductions across CKD stages G3-G5 without requiring dose adjustment, though robust cardiovascular outcome data in advanced CKD and dialysis are still lacking.
Background/Objectives: Cardiovasc{Citation}ular disease accounts for 50% of chronic kidney disease (CKD) mortality, yet fewer than 40% of patients achieve guideline LDL-cholesterol (LDL-C) targets on statins. Injectable lipid-lowering therapies (ILLTs)—PCSK9 inhibitors and inclisiran—offer 50–70% LDL-C reductions but lack comprehensive CKD-specific evidence synthesis. This systematic review evaluated ILLT efficacy, safety, and implementation across kidney function stages including dialysis. Methods: Following PROSPERO registration (CRD42024612594), we searched MEDLINE, Embase, Cochrane Library, CINAHL, and Google Scholar (1995–August 2025). Two reviewers independently screened studies using PICOS criteria: adults with CKD stages G3-G5, dialysis, or transplant recipients receiving injectable lipid therapies. Primary outcomes were LDL-C percentage change and major adverse cardiovascular events. Quality was assessed using NIH tools. Given heterogeneity, we performed narrative synthesis following SWiM guidance. Results: Eight studies (n = 28,013) met the criteria. The FOURIER trial demonstrated that evolocumab achieved 58–59% LDL-C reductions across kidney function strata (interaction p = 0.77) with preserved cardiovascular benefit (HR 0.82–0.89). Absolute risk reduction was greater in advanced CKD (2.5% vs. 1.7%), reflecting higher baseline rates. Pharmacokinetic studies showed no eGFR-exposure correlation requiring dose adjustment; evolocumab was not removed by haemodialysis. Inclisiran achieved a 67–80% PCSK9 reduction and a 35–58% LDL-C reduction across renal groups, with twice-yearly maintenance dosing. Both classes reduced non-HDL-C (45–50%), apoB (40–45%), and lipoprotein(a) (20–25%). Safety was favourable, with mild injection-site reactions (< 5%); no renal decline signals emerged. Conclusions: Evidence for injectable lipid-lowering therapies in CKD are driven largely by a single large post hoc subgroup analysis (FOURIER) and small phase 1–2 PK/PD studies, with minimal dialysis representation and no transplant data. These agents appear to provide substantial LDL-C reductions across CKD stages G3–G5 without dose adjustment, but cardiovascular and renal outcome data in advanced CKD and dialysis remain limited and should be interpreted cautiously.
No takes yet. Share an insight, caveat, or question.
Davies et al. (2026) conducted a systematic review in Chronic kidney disease (CKD) (n=28,013). Injectable lipid-lowering therapies (PCSK9 inhibitors and inclisiran) was evaluated on LDL-C percentage change and major adverse cardiovascular events. Injectable lipid-lowering therapies achieved 35-59% LDL-C reductions across CKD stages G3-G5 without dose adjustment, though cardiovascular and renal outcome data remain limited.
Synapse has enriched 10 related papers. Consider them for comparative context: